Supplementary Table 1. Association between clinicopathological features and reconstruction by initial surgery1
Billroth I (n = 79) / Billroth II (n = 43) / PAge (years) / 63.9 ± 9.4 / 60.8 ± 9.2 / 0.088
Sex / 0.113
Male / 68 (86.1%) / 41 (95.3%)
Female / 11 (13.9%) / 2 (4.7%)
Interval (years) / 11.2 ± 12.7 / 21.8 ± 12.6 / 0.001
Historical periods / 0.005
Prior periods / 19 (24.1%) / 22 (51.2%)
Latter periods / 60 (75.9%) / 21 (48.8%)
Initial gastric disease / 0.001
Benign / 15 (19.0%) / 34 (79.1%)
Cancer / 64 (81.0%) / 9 (20.9%)
Tumor location / 0.001
Anastomotic site / 16 (20.3%) / 28 (65.1%)
Non-anastomotic site / 63 (79.7%) / 15 (34.9%)
Histology / 0.756
Differentiated / 37 (46.8%) / 20 (46.5%)
Undifferentiated / 41 (51.9%) / 23 (53.5%)
Unknown / 1 (1.3%)
Lymphatic invasion / 0.153
Positive / 38 (48.1%) / 24 (55.8%)
Negative / 36 (45.6%) / 13 (30.2%)
Unclear / 5 (6.3%) / 6 (14.0%)
Venous invasion / 0.500
Positive / 49 (62.0%) / 15 (34.9%)
Negative / 25 (31.6%) / 23 (53.5%)
Unclear / 5 (6.3%) / 5 (11.6%)
Depth of invasion / 0.011
M / 18 (22.8%) / 7 (16.3%)
SM / 22 (27.8%) / 2 (4.7%)
MP / 4 (5.1%) / 6 (14.0%)
SS / 10 (12.7%) / 9 (20.9%)
SE / 18 (22.8%) / 14 (32.6%)
SI / 7 (8.9%) / 5 (11.6%)
Lymph node metastasis / 0.006
Positive / 24 (30.4%) / 24 (55.8%)
Negative / 55 (69.6%) / 19 (44.2%)
Stage / 0.011
I / 44 (55.7%) / 15 (34.9%)
II / 14 (17.7%) / 5 (11.6%)
III / 8 (10.1%) / 14 (32.6%)
IV / 13 (16.5%) / 9 (20.9%)
Operation procedure / 0.739
Total remnant gastrectomy / 74 (93.7%) / 39 (90.7%)
Local resection / 3 (3.8%) / 3 (7.0%)
Exploratory laparotomy / 1 (1.3%) / 0 (0.0%)
Bypass / 1 (1.3%) / 1 (2.3%)
Combined resection / 13 (16.5%) / 21 (48.8%) / 0.001
Spleen / 10 (12.7%) / 17 (39.5%)
Distal pancreas / 6 (6.3%) / 6 (14.0%)
Liver / 2 (2.5%) / 2 (4.7%)
Colon / 1 (1.3%) / 7 (16.3%)
Lower esophagus / 1 (1.3%) / 3 (7.0%)
Curative resection / 0.268
Yes / 67 (84.8%) / 33 (76.7%)
No / 12 (15.2%) / 10 (23.3%)
Postoperative morbidity / 18 (22.8%) / 5 (11.6%) / 0.725
Leakage / 7 (8.9%) / 2 (4.7%)
Pancreatic fistula / 5 (19.0%) / 2 (4.7%)
Wound infection / 6 (6.3%) / 4 (9.3%)
Pneumonia / 1 (1.3%) / 0 (0.0%)
Pleural effusion / 2 (2.5%) / 0 (0.0%)
Intra-abdominal abscess / 2 (2.5%) / 0 (0.0%)
Intra-abdominal bleeding / 1 (1.3%) / 0 (0.0%)
Bile fistula / 1 (1.3%) / 0 (0.0%)
Colitis / 1 (1.3%) / 0 (0.0%)
Anastomotic stenosis / 1 (1.3%) / 0 (0.0%)
Kidney failure / 0 (0.0%) / 2 (4.7%)
Liver enzyme elevation / 1 (1.3%) / 0 (0.0%)
90-day mortality / 1 (1.3%) / 2 (4.7%) / 0.283
Adjuvant chemotherapy / 15 (19.0%) / 5 (11.6%) / 0.443
Recurrence / 0.663
Liver / 1 (1.3%) / 3 (7.0%)
Lung / 3 (3.8%) / 0 (0.0%)
Peritoneum / 5 (6.3%) / 6 (14.0%)
Anastomotic site / 6 (7.6%) / 5 (11.6%)
Lymph node / 4 (5.1%) / 6 (14.0%)
Bone / 1 (1.3%) / 1 (2.3%)
Brain / 1 (1.3%) / 0 (0.0%)
Pleural dissemination / 0 (0.0%) / 1 (2.3%)
1There is an overlap in the number of organs with combined resection and recurrence.
M, mucosa; SM, submucosa; MP, muscularis propria; SS, subserosa; SE, serosa-exposed; SI, serosa-infiltrating
Supplementary Table 2. Clinicopathological features according to tumor location1
Anastomotic site (n = 44) / Non-anastomotic site (n = 78) / PAge (years) / 62.6 ± 9.0 / 62.9 ± 9.6 / 0.873
Sex
Male / 41(93.2%) / 68 (87.2%) / 0.373
Female / 3 (6.8%) / 10 (12.8%)
Interval (years) / 20.0 ± 14.1 / 12.1 ± 10.9 / 0.002
Historical periods / 0.427
Prior periods / 17 (38.6%) / 24 (30.8%)
Latter periods / 27 (61.4%) / 54 (69.2%)
Initial gastric disease / 0.001
Benign / 27 (61.4%) / 22 (28.2%)
Cancer / 17 (38.6%) / 56 (71.8%)
Initial operation / 0.001
Billroth I / 16 (36.4%) / 63 (80.8%)
Billroth II / 28 (63.6%) / 15 (19.2%)
Histology / 1.000
Differentiated / 21 (47.7%) / 36 (46.2%)
Undifferentiated / 23 (52.3%) / 41 (52.6%)
Unknown / 0 (0.0%) / 1 (1.3%)
Lymphatic invasion / 0.167
Positive / 26 (59.1%) / 36 (46.2%)
Negative / 14 (31.8%) / 35 (44.9%)
Unclear / 4 (9.1%) / 7 (9.0%)
Venous invasion / 0.306
Positive / 17 (38.6%) / 23 (29.5%)
Negative / 23 (52.3%) / 49 (62.8%)
Unclear / 4 (9.1%) / 6 (7.7%)
Depth of invasion / 0.060
M / 7 (15.9%) / 18 (23.1%)
SM / 4 (9.1%) / 20 (25.6%)
MP / 6 (13.6%) / 4 (5.1%)
SS / 10 (22.7%) / 9 (11.5%)
SE / 11 (25.0%) / 21 (26.9%)
SI / 6 (13.6%) / 6 (7.7%)
Lymph node metastasis / 0.338
Positive / 20 (45.5%) / 28 (35.9%)
Negative / 24 (54.5%) / 50 (64.1%)
Stage / 0.080
I / 18 (40.9%) / 41 (52.6%)
II / 4 (9.1%) / 15 (19.2%)
III / 12 (27.3%) / 10 (12.8%)
IV / 10 (22.7%) / 12 (15.4%)
Operation procedure / 0.004
Total remnant gastrectomy / 37 (84.1%) / 76 (97.4%)
Local resection / 5 (11.4%) / 1 (1.3%)
Exploratory laparotomy / 0 (0.0%) / 1 (1.3%)
Bypass / 2 (4.5%) / 0 (0.0%)
Combined resection / 14 (31.8%) / 20 (25.6%) / 0.530
Spleen / 11 (25.0%) / 16 (20.5%)
Distal pancreas / 7 (15.9%) / 5 (6.4%)
Liver / 1 (2.3%) / 3 (3.8%)
Colon / 7 (15.9%) / 1 (1.3%)
Lower esophagus / 0 (0.0%) / 4 (5.1%)
Curative resection / 0.148
Yes / 33 (75.0%) / 67 (85.9%)
No / 11 (25.0%) / 11 (14.1%)
Postoperative morbidity / 6 (13.6%) / 17 (21.8%) / 0.485
Leakage / 1 (2.3%) / 8 (10.3%)
Pancreatic fistula / 2 (4.5%) / 5 (6.4%)
Wound infection / 2 (4.5%) / 8 (10.3%)
Pneumonia / 0 (0.0%) / 1 (1.3%)
Pleural effusion / 0 (0.0%) / 2 (2.6%)
Intra-abdominal abscess / 0 (0.0%) / 2 (2.6%)
Intra-abdominal bleeding / 0 (0.0%) / 1 (1.3%)
Bile fistula / 0 (0.0%) / 1 (1.3%)
Colitis / 1 (2.3%) / 0 (0.0%)
Anastomotic stenosis / 0 (0.0%) / 1 (1.3%)
Kidney failure / 1 (2.3%) / 1 (1.3%)
Liver enzyme elevation / 1 (2.3%) / 0 (0.0%)
90-day mortality / 2 (4.5%) / 1 (1.3%) / 0.295
Adjuvant chemotherapy / 6 (13.6%) / 14 (17.9%) / 0.618
Recurrence / 0.982
Liver / 2 (4.5%) / 2 (2.6%)
Lung / 1 (2.3%) / 2 (2.6%)
Peritoneum / 5 (11.4%) / 6 (7.7%)
Anastomotic site / 6 (13.6%) / 5 (6.4%)
Lymph node / 6 (13.6%) / 4 (5.1%)
Bone / 1 (2.3%) / 1 (1.3%)
Brain / 0 (0.0%) / 1 (1.3%)
Pleural dissemination / 0 (0.0%) / 1 (1.3%)
1There is an overlap in the number of organs with combined resection and recurrence.
M, mucosa; SM, submucosa; MP, muscularis propria; SS, subserosa; SE, serosa-exposed; SI, serosa-infiltrating
6